C-terminal pro–endothelin-1 offers additional prognostic information in patients after acute myocardial infarction : Leicester Acute Myocardial Infarction Peptide (LAMP) Study - 15/08/11
, Onkar Dhillon, MRCP a, Joachim Struck, PhD b, Paulene Quinn, MS a, Nils G. Morgenthaler, PhD b, Ian B. Squire, MD a, Joan E. Davies, PhD a, Andreas Bergmann, PhD b, Leong L. Ng, MD aRésumé |
Background |
Endothelin-1 is elevated in heart failure (HF) and after acute myocardial infarction (AMI) and gives prognostic information on mortality. Another part of its precursor, C-terminal pro–endothelin-1 (CT-proET-1), is more stable in circulation and ex vivo. We investigated the cardiovascular prognostic value post-AMI of CT-proET-1 and compared it to N-terminal pro–B-type natriuretic peptide (NTproBNP), a marker of death and HF.
Methods |
We measured plasma CT-proET-1 and NTproBNP in 983 consecutive post-AMI patients (721 men, mean age 65.0 ± [SD] 12.2 years), 3 to 5 days after chest pain onset.
Results |
There were 101 deaths and 49 readmissions with HF during follow-up (median 343, range 0-764 days). C-terminal pro–endothelin-1 was raised in patients with death or HF compared to survivors (median [range] [pmol/L], 119.0 [14.0-671.0] vs 73.0 [4.6-431.0], P < .0001). Using a Cox proportional hazards logistic model, log CT-proET-1 (HR 6.82) and log NTproBNP (HR 2.62) were significant independent predictors of death or HF (along with age, sex, history of AMI, and therapy with β-blockers). The areas under the receiver operating curve for CT-proET-1, NTproBNP, and the logistic model with both markers were 0.76, 0.76, and 0.81 respectively. Findings were similar for death and HF as individual end points.
Conclusion |
The endothelin system is known to be activated post AMI. C-terminal pro–endothelin-1 is a powerful predictor of adverse outcome, along with NTproBNP. CT-proET-1 may represent a clinically useful marker of prognosis after AMI.
Le texte complet de cet article est disponible en PDF.Plan
| Conflicts of interest: A Bergmann holds ownership in BRAHMS AG, patent rights to the markers of the study and is a member of the board of directors of BRAHMS AG. J Struck holds patent rights to the markers and is an employee of BRAHMS AG. N Morgenthaler is an employee of BRAHMS AG. BRAHMS is a mid-sized company, based in Hennigsdorf, Germany, commercializes immunoassays, and has developed the CT-proET-1 assay, for which it owns patent rights. |
|
| Dr Sohail Q. Khan is supported by a British Heart Foundation Junior Research Fellowship (FS/03/028/15486). This study was not financed by BRAHMS AG. |
Vol 154 - N° 4
P. 736-742 - octobre 2007 Retour au numéro
Article précédent
- Dual antiplatelet agent failure: A new syndrome or clinical nonentity?
- Geoffrey D. Barnes, Jin Li, Eva Kline-Rogers, Ameeth Vedre, David F. Armstrong, James B. Froehlich, Kim A. Eagle, Hitinder S. Gurm
- Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy
- Jorge R. Alegria, Todd D. Miller, Raymond J. Gibbons, Qi-Long Yi, Salim Yusuf, for the Collabhorative Organization of RheothRx Evaluation (CORE) Trial Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?